{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:52Z","timestamp":1792785052808,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":93,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guizhou Provincial Health Commission\u2019s 2025 Science and Technology Fund","award":["gzwkj2025-240"],"award-info":[{"award-number":["gzwkj2025-240"]}],"id":[{"id":"https:\/\/ror.org\/027yzwq33","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-61081-w","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:26:24Z","timestamp":1783956384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of different highly active antiretroviral therapy regimens on immune, biochemical indicators, and viral suppression in HIV\/AIDS patients in Southwest China"],"prefix":"10.1038","volume":"16","author":[{"given":"Zongyu","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanglian","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"12","key":"61081_CR1","doi-asserted-by":"publisher","first-page":"e807","DOI":"10.1016\/S2352-3018(24)00212-1","volume":"11","author":"GBD 2021 HIV Collaborators","year":"2024","unstructured":"GBD 2021 HIV Collaborators. Global, regional, and national burden of HIV\/AIDS, 1990\u20132021, and forecasts to 2050, for 204 countries and territories: The Global Burden of Disease Study 2021. Lancet HIV. 11 (12), e807\u2013e822. https:\/\/doi.org\/10.1016\/S2352-3018(24)00212-1 (2024).","journal-title":"Lancet HIV"},{"key":"61081_CR2","doi-asserted-by":"publisher","first-page":"1277491","DOI":"10.3389\/fimmu.2023.1277491","volume":"14","author":"CM Dang","year":"2023","unstructured":"Dang, C. M. et al. Opioids exacerbate inflammation in people with well-controlled HIV. Front. Immunol. 14, 1277491. https:\/\/doi.org\/10.3389\/fimmu.2023.1277491 (2023).","journal-title":"Front. Immunol."},{"issue":"12","key":"61081_CR3","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.3390\/v13122512","volume":"13","author":"CY Lau","year":"2021","unstructured":"Lau, C. Y., Adan, M. A. & Maldarelli, F. Why the HIV reservoir never runs dry: Clonal expansion and the characteristics of HIV-infected cells challenge strategies to cure and control HIV infection. Viruses 13 (12), 2512. https:\/\/doi.org\/10.3390\/v13122512 (2021).","journal-title":"Viruses"},{"issue":"4","key":"61081_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1177\/2325957414555227","volume":"14","author":"MA Kuti","year":"2015","unstructured":"Kuti, M. A. et al. Dyslipidemia in ART-naive HIV-infected persons in Nigeria-Implications for care. J. Int. Assoc. Provid. AIDS Care 14 (4), 355\u2013359. https:\/\/doi.org\/10.1177\/2325957414555227 (2015).","journal-title":"J. Int. Assoc. Provid. AIDS Care"},{"issue":"10","key":"61081_CR5","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s40265-018-0934-2","volume":"78","author":"ED Deeks","year":"2018","unstructured":"Deeks, E. D. Darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide: A review in HIV-1 infection. drugs. Drugs 78 (10), 1013\u20131024. https:\/\/doi.org\/10.1007\/s40265-018-0934-2 (2018).","journal-title":"Drugs"},{"issue":"9","key":"61081_CR6","doi-asserted-by":"publisher","first-page":"e0305461","DOI":"10.1371\/journal.pone.0305461","volume":"19","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. The risk of dyslipidemia on PLHIV associated with different antiretroviral regimens in Huzhou. PLoS One. 19 (9), e0305461. https:\/\/doi.org\/10.1371\/journal.pone.0305461 (2024).","journal-title":"PLoS One"},{"key":"61081_CR7","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.2147\/IDR.S284917","volume":"13","author":"Y Lan","year":"2020","unstructured":"Lan, Y. et al. Absence of integrase inhibitor-associated resistance among antiretroviral therapy-na\u00efve HIV-1-infected adults in Guangdong Province, China, in 2018. Infect. Drug Resist. 13, 4389\u20134394. https:\/\/doi.org\/10.2147\/IDR.S284917 (2020).","journal-title":"Infect. Drug Resist."},{"key":"61081_CR8","doi-asserted-by":"publisher","first-page":"873408","DOI":"10.3389\/fimmu.2022.873408","volume":"13","author":"J Mart\u00ednez-Sanz","year":"2022","unstructured":"Mart\u00ednez-Sanz, J. et al. Similar CD4\/CD8 ratio recovery after initiation of dolutegravir plus lamivudine versus dolutegravir or bictegravir-based three-drug regimens in naive adults with HIV. Front. Immunol. 13, 873408. https:\/\/doi.org\/10.3389\/fimmu.2022.873408 (2022).","journal-title":"Front. Immunol."},{"issue":"3","key":"61081_CR9","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/S2352-3018(15)00006-5","volume":"2","author":"C Mussini","year":"2015","unstructured":"Mussini, C. et al. CD4\/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study. Lancet HIV 2 (3), e98\u2013e106. https:\/\/doi.org\/10.1016\/S2352-3018(15)00006-5 (2015).","journal-title":"Lancet HIV"},{"key":"61081_CR10","doi-asserted-by":"publisher","first-page":"6817325","DOI":"10.1155\/2016\/6817325","volume":"2016","author":"CR Ojha","year":"2016","unstructured":"Ojha, C. R., Shakya, G. & Dumre, S. P. Virological and immunological status of the people living with HIV\/AIDS undergoing ART treatment in Nepal. Biomed. Res. Int. 2016, 6817325. https:\/\/doi.org\/10.1155\/2016\/6817325 (2016).","journal-title":"Biomed. Res. Int."},{"key":"61081_CR11","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3389\/fimmu.2020.01541","volume":"11","author":"LX Zhang","year":"2020","unstructured":"Zhang, L. X. et al. HIV reservoir decay and CD4 recovery associated with high CD8 counts in immune restored patients on long-term ART. Front. Immunol. 11, 1541. https:\/\/doi.org\/10.3389\/fimmu.2020.01541 (2020).","journal-title":"Front. Immunol."},{"key":"61081_CR12","doi-asserted-by":"publisher","unstructured":"Kowalska, J. D., Ankiersztejn-Bartczak, M., Shepherd, L. & Mocroft, A. Cascade of care and factors associated with virological suppression among HIV-positive persons linked to care in the Test and Keep in Care (TAK) project. Infection 46(4), 533\u2013540. https:\/\/doi.org\/10.1007\/s15010-018-1154-0 (epub 2018 May 21) (2018).","DOI":"10.1007\/s15010-018-1154-0"},{"issue":"4","key":"61081_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jama.2018.8431","volume":"320","author":"MS Saag","year":"2018","unstructured":"Saag, M. S. et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA 320 (4), 379\u2013396. https:\/\/doi.org\/10.1001\/jama.2018.8431 (2018).","journal-title":"JAMA"},{"issue":"1","key":"61081_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11904-019-00480-3","volume":"17","author":"J Trivedi","year":"2020","unstructured":"Trivedi, J. et al. Recent advances in the development of integrase inhibitors for HIV treatment. Curr. HIV\/AIDS Rep. 17 (1), 63\u201375. https:\/\/doi.org\/10.1007\/s11904-019-00480-3 (2020).","journal-title":"Curr. HIV\/AIDS Rep."},{"issue":"6","key":"61081_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2174\/157016208786501526","volume":"6","author":"C Lehmann","year":"2008","unstructured":"Lehmann, C. et al. Nucleoside-free boosted double PI regimen: Significant CD4\u2009+\u2009T-cell recovery in patients with poor immunologic response despite virologic suppression. Curr. HIV Res. 6 (6), 555\u2013559. https:\/\/doi.org\/10.2174\/157016208786501526 (2008).","journal-title":"Curr. HIV Res."},{"issue":"5","key":"61081_CR16","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s10495-007-0755-3","volume":"12","author":"SR Vlahakis","year":"2007","unstructured":"Vlahakis, S. R., Bennett, S. A., Whitehead, S. N. & Badley, A. D. HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo. Apoptosis 12 (5), 969\u2013977. https:\/\/doi.org\/10.1007\/s10495-007-0755-3 (2007).","journal-title":"Apoptosis"},{"key":"61081_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11904-017-0356-x","volume":"14","author":"CO Hileman","year":"2017","unstructured":"Hileman, C. O. & Funderburg, N. T. Inflammation, immune activation, and antiretroviral therapy in HIV. Curr. HIV\/AIDS Rep. 14, 93\u2013100. https:\/\/doi.org\/10.1007\/s11904-017-0356-x (2017).","journal-title":"Curr. HIV\/AIDS Rep."},{"issue":"9","key":"61081_CR18","doi-asserted-by":"publisher","first-page":"e016886","DOI":"10.1136\/bmjopen-2017-016886","volume":"7","author":"SS Lee","year":"2017","unstructured":"Lee, S. S., Wong, N. S., Wong, B. C. K., Wong, K. H. & Chan, K. C. W. Combining CD4 recovery and CD4: CD8 ratio restoration as an indicator for evaluating the outcome of continued antiretroviral therapy: An observational cohort study. BMJ Open. 7 (9), e016886. https:\/\/doi.org\/10.1136\/bmjopen-2017-016886 (2017).","journal-title":"BMJ Open."},{"key":"61081_CR19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1186\/s12879-017-2864-0","volume":"17","author":"S Sinha","year":"2017","unstructured":"Sinha, S. et al. Nevirapine- versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: A multi-centre study. BMC Infect. Dis. 17, 761. https:\/\/doi.org\/10.1186\/s12879-017-2864-0 (2017).","journal-title":"BMC Infect. Dis."},{"issue":"10","key":"61081_CR20","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1093\/jac\/dkv183","volume":"70","author":"N Apostolova","year":"2015","unstructured":"Apostolova, N. et al. Efavirenz and the CNS: What we already know and questions that need to be answered. J. Antimicrob. Chemother. 70 (10), 2693\u20132708. https:\/\/doi.org\/10.1093\/jac\/dkv183 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"61081_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12951-018-0349-y","volume":"16","author":"NJ Liptrott","year":"2018","unstructured":"Liptrott, N. J. et al. Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems. J. Nanobiotechnol. 16, 22. https:\/\/doi.org\/10.1186\/s12951-018-0349-y (2018).","journal-title":"J. Nanobiotechnol."},{"issue":"11","key":"61081_CR22","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1093\/jac\/dku262","volume":"69","author":"A Blas-Garc\u00eda","year":"2014","unstructured":"Blas-Garc\u00eda, A. et al. Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: A comparison with efavirenz. J. Antimicrob. Chemother. 69 (11), 2995\u20133000. https:\/\/doi.org\/10.1093\/jac\/dku262 (2014).","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"61081_CR23","doi-asserted-by":"publisher","first-page":"e01763","DOI":"10.1128\/AAC.01763-17","volume":"61","author":"S Serrano-Villar","year":"2017","unstructured":"Serrano-Villar, S., Caruana, G., Zlotnik, A., P\u00e9rez-Molina, J. A. & Moreno, S. Effects of maraviroc versus efavirenz in combination with zidovudine-lamivudine on the CD4\/CD8 ratio in treatment-naive HIV-infected individuals. Antimicrob. Agents Chemother. 61 (12), e01763\u2013e01717. https:\/\/doi.org\/10.1128\/AAC.01763-17 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"61081_CR24","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.cmi.2017.11.016","volume":"24","author":"JR Blanco","year":"2018","unstructured":"Blanco, J. R., Alejos, B. & Moreno, S. Impact of dolutegravir and efavirenz on immune recovery markers: Results from a randomized clinical trial. Clin. Microbiol. Infect. 24 (8), 900\u2013907. https:\/\/doi.org\/10.1016\/j.cmi.2017.11.016 (2018).","journal-title":"Clin. Microbiol. Infect."},{"issue":"8b","key":"61081_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.7196\/SAMJ.2019.v109i8b.13829","volume":"109","author":"C Durandt","year":"2019","unstructured":"Durandt, C. et al. HIV and haematopoiesis. S Afr. Med. J. 109 (8b), 40\u201345. https:\/\/doi.org\/10.7196\/SAMJ.2019.v109i8b.13829 (2019).","journal-title":"S Afr. Med. J."},{"issue":"9","key":"61081_CR26","doi-asserted-by":"publisher","first-page":"e0239215","DOI":"10.1371\/journal.pone.0239215","volume":"15","author":"A Gebreweld","year":"2020","unstructured":"Gebreweld, A., Fiseha, T., Girma, N., Haileslasie, H. & Gebretsadik, D. Prevalence of cytopenia and its associated factors among HIV-infected adults on highly active antiretroviral therapy at Mehal Meda Hospital, North Shewa Zone, Ethiopia. PLoS One. 15 (9), e0239215. https:\/\/doi.org\/10.1371\/journal.pone.0239215 (2020).","journal-title":"PLoS One"},{"issue":"3","key":"61081_CR27","doi-asserted-by":"publisher","first-page":"ofu108","DOI":"10.1093\/ofid\/ofu108","volume":"1","author":"J Lo","year":"2014","unstructured":"Lo, J. et al. High-density lipoprotein-mediated cholesterol efflux capacity is improved by treatment with antiretroviral therapy in acute human immunodeficiency virus infection. Open. Forum Infect. Dis. 1 (3), ofu108. https:\/\/doi.org\/10.1093\/ofid\/ofu108 (2014).","journal-title":"Open. Forum Infect. Dis."},{"key":"61081_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2174\/1874192401105010049","volume":"5","author":"ER Feeney","year":"2011","unstructured":"Feeney, E. R. & Mallon, P. W. HIV and HAART-associated dyslipidemia. Open. Cardiovasc. Med. J. 5, 49\u201363. https:\/\/doi.org\/10.2174\/1874192401105010049 (2011).","journal-title":"Open. Cardiovasc. Med. J."},{"issue":"9","key":"61081_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s11883-023-01125-y","volume":"25","author":"V Bazioti","year":"2023","unstructured":"Bazioti, V., Halmos, B. & Westerterp, M. T-cell cholesterol accumulation, aging, and atherosclerosis. Curr. Atheroscler. Rep. 25 (9), 527\u2013534. https:\/\/doi.org\/10.1007\/s11883-023-01125-y (2023).","journal-title":"Curr. Atheroscler. Rep."},{"issue":"8","key":"61081_CR30","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1468-1293.2012.00996.x","volume":"13","author":"FM Islam","year":"2012","unstructured":"Islam, F. M., Wu, J., Jansson, J. & Wilson, D. P. Relative risk of cardiovascular disease among people living with HIV: A systematic review and meta-analysis. HIV Med. 13 (8), 453\u2013468. https:\/\/doi.org\/10.1111\/j.1468-1293.2012.00996.x (2012).","journal-title":"HIV Med."},{"issue":"5","key":"61081_CR31","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s10620-007-9999-6","volume":"53","author":"RK Sterling","year":"2008","unstructured":"Sterling, R. K., Chiu, S., Snider, K. & Nixon, D. The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections. Dig. Dis. Sci. 53 (5), 1375\u20131382. https:\/\/doi.org\/10.1007\/s10620-007-9999-6 (2008).","journal-title":"Dig. Dis. Sci."},{"issue":"12","key":"61081_CR32","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.cgh.2010.08.024","volume":"8","author":"JC Price","year":"2010","unstructured":"Price, J. C. & Thio, C. L. Liver disease in the HIV-infected individual. Clin. Gastroenterol. Hepatol. 8 (12), 1002\u20131012. https:\/\/doi.org\/10.1016\/j.cgh.2010.08.024 (2010).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"5","key":"61081_CR33","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1086\/655681","volume":"51","author":"RD Cooper","year":"2010","unstructured":"Cooper, R. D. et al. Systematic review and meta-analysis: Renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin. Infect. Dis. 51 (5), 496\u2013505. https:\/\/doi.org\/10.1086\/655681 (2010).","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"61081_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1423-0127-20-61","volume":"20","author":"P Abraham","year":"2013","unstructured":"Abraham, P., Ramamoorthy, H. & Isaac, B. Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate-induced mitochondrial damage and increased oxido-nitrosative stress in the kidney. J. Biomed. Sci. 20 (1), 61. https:\/\/doi.org\/10.1186\/1423-0127-20-61 (2013).","journal-title":"J. Biomed. Sci."},{"issue":"8","key":"61081_CR35","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1111\/j.1476-5381.2010.00866.x","volume":"160","author":"N Apostolova","year":"2010","unstructured":"Apostolova, N. et al. Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells. Br. J. Pharmacol. 160 (8), 2069\u20132084. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00866.x (2010).","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"61081_CR36","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/phar.1852","volume":"36","author":"TT Vo","year":"2016","unstructured":"Vo, T. T. & Varghese Gupta, S. Role of cytochrome P450 2B6 pharmacogenomics in determining efavirenz-mediated central nervous system toxicity, treatment outcomes, and dosage adjustments in patients with human immunodeficiency virus infection. Pharmacotherapy 36 (12), 1245\u20131254. https:\/\/doi.org\/10.1002\/phar.1852 (2016).","journal-title":"Pharmacotherapy"},{"issue":"4","key":"61081_CR37","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/j.1365-2125.2008.03238.x","volume":"66","author":"SA Pereira","year":"2008","unstructured":"Pereira, S. A. et al. Efavirenz concentrations in HIV-infected patients with and without viral hepatitis. Br. J. Clin. Pharmacol. 66 (4), 551\u2013555. https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03238.x (2008).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"61081_CR38","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s12876-022-02305-x","volume":"22","author":"LE Abongwa","year":"2022","unstructured":"Abongwa, L. E. et al. Risk factors of severe hepatotoxicity among HIV-1 infected individuals initiated on highly active antiretroviral therapy in the Northwest Region of Cameroon. BMC Gastroenterol. 22 (1), 286. https:\/\/doi.org\/10.1186\/s12876-022-02305-x (2022).","journal-title":"BMC Gastroenterol."},{"issue":"2","key":"61081_CR39","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/jps.24564","volume":"105","author":"T De Bruyn","year":"2016","unstructured":"De Bruyn, T., Stieger, B., Augustijns, P. F. & Annaert, P. P. Clearance prediction of HIV protease inhibitors in man: Role of hepatic uptake. J. Pharm. Sci. 105 (2), 854\u2013863. https:\/\/doi.org\/10.1002\/jps.24564 (2016).","journal-title":"J. Pharm. Sci."},{"issue":"Suppl 3","key":"61081_CR40","doi-asserted-by":"publisher","first-page":"S279","DOI":"10.1086\/533414","volume":"197","author":"MS Sulkowski","year":"2008","unstructured":"Sulkowski, M. S. Management of hepatic complications in HIV-infected persons. J. Infect. Dis. 197 (Suppl 3), S279\u2013S293. https:\/\/doi.org\/10.1086\/533414 (2008).","journal-title":"J. Infect. Dis."},{"issue":"2","key":"61081_CR41","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/cpt.3529","volume":"118","author":"J Dong","year":"2025","unstructured":"Dong, J. et al. Inhibition of OATP1B1\/3 rather than UGT1A1 may be the major cause of the bilirubin elevation after atazanavir administration. Clin. Pharmacol. Ther. 118 (2), 497\u2013509. https:\/\/doi.org\/10.1002\/cpt.3529 (2025).","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61081-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61081-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61081-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:25:02Z","timestamp":1791980702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61081-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["61081"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-61081-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the retrospective nature of the study, the Ethics Committee of Guiyang Public Health Clinical Center waived the requirement for informed consent. The study strictly adhered to the ethical standards of the Declaration of Helsinki and has been approved by the Ethics Committee of Guiyang Public Health Clinical Center (Approval No: 2025-73).","order":2,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"32156"}}